Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

rrent business model and working with our management team to find approaches to help us operate more efficiently over the long-term, and continue as a driving force in global healthcare."

2007 Fourth Quarter and Full Year Product Highlights

Set forth below is a table of net revenue for Wyeth's principal products for the 2007 fourth quarter and full year together with the percentage changes from the comparable period in the prior year:


Three Months Ended Full Year Ended

12/31/2007 12/31/2007

Increase/ Increase/

($ in millions) (Decrease) ($ in millions) (Decrease)

Principal Products

Effexor $968 3% $3,794 2%

Prevnar 556 11% 2,439 24%

Enbrel (outside the

U.S. and Canada) 565 36% 2,045 36%

Protonix 461 10% 1,911 6%

Nutrition 393 28% 1,443 20%

Alliance Revenue (1) 321 (13)% 1,294 (3)%

Zosyn/Tazocin 292 17% 1,137 17%

Premarin Family 264 1% 1,055 0%

Centrum 204 13% 705 7%

Advil 186 8% 684 10%

(1) Alliance revenue reflects revenue to Wyeth derived from sales of

Enbrel (in the United States and Canada), Altace and the CYPHER stent.

Product Highlights

Enbrel(R) continued to post strong revenue growth during 2007. Enbrel sales in the United States and Canada, reported by Wyeth's marketing part

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
(Date:9/2/2015)... , Sept. 2, 2015 Australian prostate cancer ... prestigious Australian science prize recognising ,outstanding, science that uses ... to globally launch a novel prostate cancer diagnostic test ... high level consortium taking out the peer-reviewed Australian Museum ... Research. This prize is awarded for ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's new $100,000 ... to energy process and continue to contribute to the sustainability of our natural ... to Energy process has been operating at their Mexico facility, Recicladora Temarry, for ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... EVRY, France, May 5 Novagali Pharma, ... the Company,s,Investigational New Drug Application (IND) to ... (Nova21027), for the treatment of glaucoma has ... Administration (FDA). Catioprost(R) is a,topical ocular proprietary ...
... Insmed Inc. (Nasdaq: INSM ), a ... from The NASDAQ Stock Market that it has regained ... requirement, and further, that it currently complies with all ... with the bid price rule, the Company was required ...
... lamps have been used to control outbreaks of measles, ... and hospitals since the 1930,s. UVGI (Ultraviolet Germicidal Irradiation) ... 1955 Mumps epidemic and helped eliminate a Varicella (Chicken ... recently, UVGI units were installed into Hong Kong hospitals ...
Cached Biology Technology:Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2Insmed Regains NASDAQ Compliance 2Swine Flu Fears Generate Interest in UV Disinfection Technologies...Again 2
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... and instead reduce fossil-fuel use for the sake of the ... the University of Washington and one from the University of ... issue of the journal Nature (Jan. 26) that ... the environment as a reason to curb the use of ...
... MIT researchers have discovered that certain photosynthetic ocean ... viruses are really con artists carrying genetic material taken ... host into using its own machinery to activate the ... relationship. The con occurs when a grifter ...
... officers can now register online to the 2012 General ... brings together over 10,000 scientists from all over the ... and space sciences. EGU,s General Assembly is an ... recent developments in topics as diverse as shale gas ...
Cached Biology News:Commentary in Nature: Can economy bear what oil prices have in store? 2Commentary in Nature: Can economy bear what oil prices have in store? 3Viruses con bacteria into working for them 2Viruses con bacteria into working for them 3European Geosciences Union General Assembly, April 22-27, 2012, Vienna, Austria 2
... The Genome Sequencer 20 System revolutionizes DNA ... parallel fashion. The Genome Sequencer 20 ... Reagents and consumables for library construction, ... mapping and de novo assembly ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... Normal Human Serum-Single Donor • Human ... who are found to be negative by ... (s) (HIV-1Ag), Antibodies to Human Immunodeficiency Virus ... Nonreactive for Hepatitis B Surface Antigen (HbsAg) ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
Biology Products: